Access count of this item: 736

Files in This Item:
File Description SizeFormat 
45_811.pdf470.02 kBAdobe PDFView/Open
Title: 難治性精巣腫瘍に対する新規抗癌剤による救済化学療法の現状
Other Titles: The salvage chemotherapy for refractory testicular cancer with novel anticancer agents
Authors: 三木, 恒治  KAKEN_name
野本, 剛史  KAKEN_name
中川, 修一  KAKEN_name
中尾, 昌宏  KAKEN_name
野々村, 祝夫  KAKEN_name
高田, 剛  KAKEN_name
細木, 茂  KAKEN_name
古武, 敏彦  KAKEN_name
Author's alias: MIKI, Tsuneharu
NOMOTO, Takeshi
NAKAGAWA, Shuichi
NAKAO, Masahiro
NONOMURA, Norio
TAKADA, Tsuyoshi
SAIKI, Shigeru
KOTAKE, Toshihiko
Keywords: Testicular cancer
CPT-11
Salvage chemotherapy
Issue Date: Nov-1999
Publisher: 泌尿器科紀要刊行会
Journal title: 泌尿器科紀要
Volume: 45
Issue: 11
Start page: 811
End page: 814
Abstract: Despite the generally high cure rate in patients with metastatic testicular cancer, 20% to 30% of treated patients will become candidates for salvage chemotherapy. We reviewed the recent salvage chemotherapy trials of refractory diseases. CPT-11 is a new derivative of camptothecin and has activity in a variety of solid tumors. We evaluated the antitumor effect of combination chemotherapy using CDDP and CPT-11 against refractory testicular cancer. Fourteen patients who failed to achieve complete remission with salvage chemotherapy were treated with combination chemotherapy with CPT-11 and CDDP or 254-S (nedaplatin) as third line chemotherapy. Six patients remain alive and disease-free and 5 patients died of disease. The combination of CPT-11 and either CDDP or nedaplatin was significantly more effective than other salvage therapy regimens such as VIP. Paclitaxel, ifosfamide, etoposide regimens were also effective in patients with refractory testicular tumors. We concluded that these combination regimens demonstrated significant activity against refractory testicular tumor and further investigation is warranted.
URI: http://hdl.handle.net/2433/114150
PubMed ID: 10637749
Appears in Collections:Vol.45 No.11

Show full item record

Export to RefWorks


Export Format: 


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.